Seohun Kyun, CEO of Yeongwon Inter, "Antibacterial New Product Development Completed... Targeting the US Market with BF Labs"

Antibacterial Yarn 'Dermalon' Attracts Domestic and International Apparel Companies' Love Calls
BF Labs Acquisition Paves Way for US Market Entry

Seohun Kyun, CEO of Yeongwon International.

"In September last year, we completed the development of the antimicrobial yarn 'Dermalon' and began its commercialization. We are currently planning products using Dermalon with domestic and international brand companies, and we are also working with Spanx, the number one shapewear company in the United States."

On the 22nd, Seo Heon-gyun, CEO of Youngone International, selected as the preferred negotiator for the change of the largest shareholder of the KOSDAQ-listed company BF Labs, revealed plans after acquiring BF Labs. BF Labs announced a public sale on the 30th of last month and selected Youngone International as the preferred negotiator on the 10th.

Seo Heon-gyun, CEO of Youngone International, stated, "Our company is an OEM (Original Equipment Manufacturer) and ODM (Original Design Manufacturer) for apparel, providing consulting from design planning and production to distribution." He added, "Our clients' brands are sold at department stores, including Musinsa, the number one apparel platform in Korea."

CEO Seo said, "Youngone International provides customized services by analyzing trends for clients, enabling us to quickly lead design development compared to other companies." He continued, "Based on this, we have achieved an average sales revenue of 9 billion KRW over the past three years, and in 2025, we plan to increase sales by signing a strategic supply contract worth 20 billion KRW with a domestic brand company."

Regarding the reason for participating in the acquisition of the listed company BF Labs, CEO Seo explained it was to target the global market. He said, "In February, Spanx, the world's top American underwear brand, recognized our technological capabilities and requested exclusive supply rights in the U.S. However, they had doubts about whether a small company could sustain this business." He added, "As a result, while seeking a partner to secure global competitiveness, we learned about the sale of the listed company BF Labs and thought it was a great opportunity to target the global market."

After acquiring BF Labs, he plans to boost performance based on Youngone International's new antimicrobial Dermalon. Dermalon is a yarn that incorporates the antimicrobial ingredient, human-friendly 'zinc,' directly inside the yarn during its initial production, giving the yarn itself antimicrobial properties. Unlike other products that apply antimicrobial coatings externally, which gradually lose functionality through washing, Dermalon's antimicrobial function is based on zinc, a human-friendly material, and features semi-permanent durability.

He said, "Our own experiments showed that even after more than 50 washes, garments made with Dermalon retain 99.9% antimicrobial function and 99.9% UV protection." He added, "In the future fashion market, securing market leadership using new materials is crucial, so we are currently receiving love calls from global brands."

Furthermore, CEO Seo stated, "We have signed an MOU with Hwasung Chemical, which manufactures products for global brands such as Adidas and New Balance, preparing to leap into the global market." He also revealed, "We are planning shoes insoles, underwear, and apparel using 'Dermalon' fabric with the outdoor brand Black Yak INC."

Finally, he emphasized, "To normalize BF Labs, sales and performance are ultimately important." He stressed, "Starting with Dermalon, we will vertically integrate yarn, fabric, planning, design, production, and supply to focus on targeting the global market."

This content was produced with the assistance of AI translation services.